(Q36510136)

14 August 2017

Clinical outcome and prognostic factors for patients treated within the context of a phase I study: the Royal Marsden Hospital experience (English)

1 reference

14 August 2017

H-T Arkenau

1

1 reference

14 August 2017

D Olmos

2

1 reference

14 August 2017

J E Ang

3

1 reference

14 August 2017

J de Bono

4

1 reference

14 August 2017

I Judson

5

1 reference

14 August 2017

S Kaye

6

1 reference

14 August 2017

language of work or name

English

0 references

publication date

18 March 2008

1 reference

British Journal of Cancer

14 August 2017

1 reference

14 August 2017

98

1 reference

14 August 2017

6

1 reference

14 August 2017

1029-1033

1 reference

https://scigraph.springernature.com/pub.10.1038/sj.bjc.6604218

14 August 2017

0 references

cites work

Comparison of prognostic factors in patients in phase I trials of cytotoxic drugs vs new noncytotoxic agents.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2275488

Relationship between objective responses in phase I trials and potential efficacy of non-specific cytotoxic investigational new drugs

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2275488

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2275488

Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the Prostate-Specific Antigen Working Group.

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2275488

Risks and benefits of phase 1 oncology trials, 1991 through 2002.

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2275488

Trends in the risks and benefits to patients with cancer participating in phase 1 clinical trials.

21 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2275488

Nonparametric Estimation from Incomplete Observations

21 September 2018

1 reference

Crossref

https://api.crossref.org/works/10.1038%2FSJ.BJC.6604218

Multivariable analysis of prognostic factors for toxicity and survival for patients enrolled in phase I clinical trials

21 January 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/18349817

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Prognostic factors among cancer patients with good performance status screened for phase I trials

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/18349817

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Survival and prognostic factors in lung cancer patients treated in phase I trials: Japanese experience

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/18349817

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1038/SJ.BJC.6604218

1 reference

14 August 2017

1 reference

14 August 2017

1 reference